BP Pumps Money Into Unlikely Projects, From Plants To Lasers

Thanks to physicist Don Braben, the oil giant funds Nobeists and little-known scientists when no one will LONDON—Harvard chemist Dudley Herschbach was reading a copy of Physics Today one day in 1981 when he came across an article on quantum chromodynamics. It explained how physicists use dimensional contraction to calculate the energy levels of subatomic particles. Intrigued, the soon-to-be Nobel laureate thought this might make a good exercise for his chemistry students to apply to atom

Written byRichard Stevenson
| 7 min read

Register for free to listen to this article
Listen with Speechify
0:00
7:00
Share

LONDON—Harvard chemist Dudley Herschbach was reading a copy of Physics Today one day in 1981 when he came across an article on quantum chromodynamics. It explained how physicists use dimensional contraction to calculate the energy levels of subatomic particles. Intrigued, the soon-to-be Nobel laureate thought this might make a good exercise for his chemistry students to apply to atomic electron levels. To his astonishment, he found that with a handheld calculator he was getting more accuracy than legions of theoretical chemists could manage with their supercomputers.

Having found an “easy” approach to a tough problem, Herschbach couldn’t wait to plunge into subatomic energy levels. But here came a snag to pursue the investigation further, he needed big bucks and a substantial amount of time to devote to the problem, and the classic funding sources wouldn’t help. Three times the National Science Foundation turned down applications for funding from an about-to-be ...

Interested in reading more?

Become a Member of

The Scientist Logo
Receive full access to digital editions of The Scientist, as well as TS Digest, feature stories, more than 35 years of archives, and much more!
Already a member? Login Here

Meet the Author

Published In

Share
February 2026

A Stubborn Gene, a Failed Experiment, and a New Path

When experiments refuse to cooperate, you try again and again. For Rafael Najmanovich, the setbacks ultimately pushed him in a new direction.

View this Issue
Human-Relevant In Vitro Models Enable Predictive Drug Discovery

Advancing Drug Discovery with Complex Human In Vitro Models

Stemcell Technologies
Redefining Immunology Through Advanced Technologies

Redefining Immunology Through Advanced Technologies

Ensuring Regulatory Compliance in AAV Manufacturing with Analytical Ultracentrifugation

Ensuring Regulatory Compliance in AAV Manufacturing with Analytical Ultracentrifugation

Beckman Coulter Logo
Conceptual multicolored vector image of cancer research, depicting various biomedical approaches to cancer therapy

Maximizing Cancer Research Model Systems

bioxcell

Products

Sino Biological Logo

Sino Biological Pioneers Life Sciences Innovation with High-Quality Bioreagents on Inside Business Today with Bill and Guiliana Rancic

Sino Biological Logo

Sino Biological Expands Research Reagent Portfolio to Support Global Nipah Virus Vaccine and Diagnostic Development

Beckman Coulter

Beckman Coulter Life Sciences Partners with Automata to Accelerate AI-Ready Laboratory Automation

Refeyn logo

Refeyn named in the Sunday Times 100 Tech list of the UK’s fastest-growing technology companies